EP1077989A4 - Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene - Google Patents

Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene

Info

Publication number
EP1077989A4
EP1077989A4 EP99921914A EP99921914A EP1077989A4 EP 1077989 A4 EP1077989 A4 EP 1077989A4 EP 99921914 A EP99921914 A EP 99921914A EP 99921914 A EP99921914 A EP 99921914A EP 1077989 A4 EP1077989 A4 EP 1077989A4
Authority
EP
European Patent Office
Prior art keywords
new
associated antigen
tumor associated
expressed gene
ubiquitously expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921914A
Other languages
German (de)
French (fr)
Other versions
EP1077989A1 (en
Inventor
Den Eynde Benoit Van
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1077989A1 publication Critical patent/EP1077989A1/en
Publication of EP1077989A4 publication Critical patent/EP1077989A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99921914A 1998-05-13 1999-05-13 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene Withdrawn EP1077989A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8531898P 1998-05-13 1998-05-13
US85318P 1998-05-13
PCT/US1999/010424 WO1999058546A1 (en) 1998-05-13 1999-05-13 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene

Publications (2)

Publication Number Publication Date
EP1077989A1 EP1077989A1 (en) 2001-02-28
EP1077989A4 true EP1077989A4 (en) 2002-01-02

Family

ID=22190806

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921914A Withdrawn EP1077989A4 (en) 1998-05-13 1999-05-13 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene

Country Status (5)

Country Link
EP (1) EP1077989A4 (en)
JP (1) JP2002514400A (en)
AU (1) AU3900399A (en)
CA (1) CA2328405A1 (en)
WO (1) WO1999058546A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3231442B1 (en) * 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
CN102245773B (en) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 Antibodies that specifically block the biological activity of a tumor antigen
BR112013025198A2 (en) 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. kidney-associated antigen 1 antibodies and antigen-binding fragments thereof
KR102102239B1 (en) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 Method for treating breast cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010577A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
WO1996029409A2 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010577A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
WO1996029409A2 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9958546A1 *

Also Published As

Publication number Publication date
EP1077989A1 (en) 2001-02-28
WO1999058546A1 (en) 1999-11-18
JP2002514400A (en) 2002-05-21
CA2328405A1 (en) 1999-11-18
AU3900399A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
ZA9811820B (en) Interlocking tiles.
GB9930397D0 (en) Profile formation
EP1062191A4 (en) Alkylaromatics production
GB9901348D0 (en) Intelligent production riser
EP1077989A4 (en) Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
PL340374A1 (en) Tanatin encoding gene
AU2001289674A1 (en) New nucleotide sequences coding for the lysr1 gene
GB9804065D0 (en) Tumour associated antigen 791Tgp72
EP1027929A4 (en) Catalyst for the production of acrylonitrile
HU0100131D0 (en) Novel nucleotide sequences coding for the ptsh-gene
HUP0004027A2 (en) New tissue-specific calpaines, their production and their use
GB2332164A9 (en) Continuous band manufacture
AU2001289807A1 (en) Nucleotide sequences coding for the pstc2 gene
ZA200007078B (en) New nucleotide sequences coding for the glk-gene.
AU2001279804A1 (en) Nucleotide sequences coding for the hisc2 gene
EP1063290A4 (en) Novel dicarbonylreductase and gene encoding the same
AU2001293723A1 (en) Nucleotide sequences coding for the dep33 gene
EP1069186A4 (en) Gene encoding desulfurases
GB2382832B (en) Profile formation
TW328844U (en) Intelligent detachable hard disk case
AU5443099A (en) Gene encoding cdw108
GB9617881D0 (en) Interlocking brick
IL148104A0 (en) Polycarbonate slabs
EP1225220A4 (en) Dna encoding endo-beta-galactosidase
PL346375A1 (en) Method of terminating the ends of protectively braided ropes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011113

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/02 A, 7C 12Q 1/68 B, 7C 12P 21/04 B, 7C 12N 1/20 B, 7C 12N 15/00 B, 7C 07K 14/47 B

17Q First examination report despatched

Effective date: 20021210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1033322

Country of ref document: HK